Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against

Thrombosis and Haemostasis

Volumn 96, Issue 4, 2006, Pages 413-416

  Weber, Artur Aron ^a   Hohlfeld, Thomas ^a   Harder, Sebastian ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Arterial thrombosis; Clinical studies; Haemostatis; Inflammation; Lipid mediators

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; ROFECOXIB;

ANALGESIC ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG ANTAGONISM; DRUG COMPETITION; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG USE; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STROKE; SYSTEMATIC REVIEW; THROMBOSIS;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; ASPIRIN; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL HEMORRHAGE; HUMANS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; THROMBOSIS; TICLOPIDINE;

EID: 33749823790     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-07-0445     Document Type: Article

References (23)

1. Wadman M. How does a painkiller harm the heart? Nature 2006; 441: 262.
2. Grosser T, Fries S, FitzGerald G. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15.
3. DeWitt. COX-2-selective inhibitors: the new super aspirins. Mol Pharmacol 1999; 55: 625-31.
4. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: non-selective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005; 165: 171-7.
5. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104-10.
6. Chan FK, LCT Hung, BY Suen, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: Results of a randomized double-blind trial. Gastroenterology 2004; 127: 103-43.
7. Scheinmann JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701-10.
8. Solomon SD, McMurray JJ, Pfeffer MA, et al. for the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
9. Bresalier RS, Sandler RS, Quan H, et al. for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
10. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006; 332: 1302-8.
11. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163: 481-6.
12. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 157-64.
13. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81.
14. Hippisley-Cox J, Coupoland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br Med J 2005; 330: 1366-70.
15. Johnsen SP, Larsson H, Throne RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165: 978-84.
16. Farkouh ME, Kirshner H, Harrington RA, et al. on behalf of the TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-84.
17. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006; 27: 1657-63.
18. Hawkey CJ, Hawkey GM, Everitt S, et al. Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol 2006; 61: 730-7.
19. Fischer LM, Schlienger RG, Matter CM, et al. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004; 164: 2472-6.
20. Smyth EM, Burke A, FitzFerald GA. Lipid-derived autacoids: Eisosanoids and platelet-activating factor. In: Brunton LL, Lazo JS, Parker KL (Eds). Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill, New York 2005, pp. 653-70.
21. Catella-Lawson F, Reilly M, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
22. Fiorucci S, Distrutti E, de Lima OM, et al. Relative contribution of acetylated cyclooxgenase (COX)-2 and 5-lipoxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J 2003; 17: 1171-3.
23. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.